Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480)
Salud · Biotecnología · CN
15,30 HK$
0,00 % hoy · -29,8 % 1 año
Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 387,91 M $ y tiene 193 empleados.
En los últimos doce meses la acción ha bajado un 29,8 % y ha cotizado entre 12,00 y 25,98.
Tweenvest puntúa a Beijing Luzhu Biotechnology Co., Ltd. en cuatro factores: calidad 50/100, valor 64/100. Su punto más fuerte es valor.
Evolución de la cotización de 2480
Cifras clave
- Capitalización
- 387,91 M $
- Ingresos (últ. 12 m)
- —
- PER
- -20,13
- BPA
- -0,78
- Rent. por dividendo
- —
- Beta (5 años)
- -0,66
- Máximo 52 semanas
- 25,98 HK$
- Mínimo 52 semanas
- 12,00 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 198,91 M
- Empleados
- 193
- Próximos resultados
- —
Sobre Beijing Luzhu Biotechnology Co., Ltd.
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
- ISIN
- CNE100005YD8
- Fundada en
- 2001
- Cotiza desde
- 8 may 2023
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| SanBio Company LimitedTSE: 4592 | 395,95 M $ | 808,00 ¥ | 0,00 % |
| Edding Genor Group Holdings LimitedSEHK: 6998 | 394,79 M $ | 1,55 HK$ | +1,97 % |
| Pharmicell Co., Ltd.KOSE: A005690 | 389,17 M $ | 8670,00 ₩ | +1,05 % |
| Landfar Bio-medicine Co., LtdSZSE: 000504 | 388,11 M $ | 7,85 CN¥ | -4,96 % |
| Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022 | 387,49 M $ | 4,99 CN¥ | -1,96 % |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | 387,41 M $ | 6,70 $ | -6,03 % |
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | 386,54 M $ | 15,41 CN¥ | -1,85 % |
| Opus Genetics, Inc.NasdaqCM: IRD | 384,68 M $ | 3,98 $ | -1,97 % |